<DOC>
	<DOCNO>NCT01621971</DOCNO>
	<brief_summary>Our main hypothesis inhalation milrinone reduce elevate pulmonary arterial pressure due severe mitral valve regurgitation without compromise systemic hemodynamics . Therefore , effect brief inhaled milrinone ( IH ) pulmonary artery pressure determine compare intravenous milrinone ( IV ) severe mitral regurgitation patient undergoing mitral valve surgery .</brief_summary>
	<brief_title>Effect Brief Nebulization Milrinone Pulmonary Arterial Pressure Before Cardiopulmonary Bypass Mitral Valve Surgery Patients</brief_title>
	<detailed_description>Perioperative pulmonary hypertension ( PHT ) , independent risk factor cardiac surgery , 1,2 frequently associate chronic mitral valve regurgitation tend produce right ventricular ( RV ) dysfunction . Worsening PHT , sensitive increase RV afterload , reduces right coronary perfusion pressure , exacerbate RV dysfunction , compromise leave ventricular ( LV ) preload systemic perfusion pressure . 3,4 Although intravenous ( IV ) milrinone prefer treat PHT due beneficial effect enhance myocardial contractability without increase heart rate-related myocardial oxygen consumption , 5-7 frequent association systemic vasodilation require additional vasoconstrictor therapy maintain optimal perfusion pressure.8-10 Selective pulmonary vasodilation , reduce RV afterload without systemic arterial vasodilation , important manage PHT accompany RV dysfunction.11 A study report nebulized inhaled ( IH ) milrinone ( 1 mg/ml ) produce dose-dependent selective pulmonary vasodilatation postoperative PHT intensive care unit.12 If IH milrinone pre-cardiopulmonary bypass ( CPB ) period produce selective pulmonary vasodilation patient PHT undergo mitral valve surgery , would beneficial option manage intraoperative PHT . Our main hypothesis brief inhale milrinone could reduce pulmonary arterial pressure without systemic side effect well intravenous milrinone elevate pulmonary artery pressure patient . The aim study determine effect hemodynamic administer IH compare IV milrinone patient elevate pulmonary artery pressure due severe mitral regurgitation undergo mitral valve surgery . Materials Methods Experimental Groups Adult patient PHT ( systolic PAP &gt; 50 mmHg estimate velocity tricuspid valve regurgitation preoperative transthoracic echocardiography ) undergo mitral valve surgery chronic mitral regurgitation enrol study obtain approval institutional research board provide write informed consent . Preoperative exclusion criterion include preoperative supraventricular tachycardia ( SVT ) , atrial fibrillation , atrial flutter , multiple ventricular ectopic contraction , continuous inotropic support , LV ejection fraction ( EF ) &lt; 30 % , emergent surgery , obstructive cardiomyopathy , bleed diatheses , bronchial asthma biochemical evidence hepatic disease renal impairment . The pharmacist implement randomization process group patient give enrolled patient , patient identification number ( PIN ) . Then , patient stratify PIN 1:1 ratio receive IH ( Primacor , Sanofi-Synthelabo Canada Inc. , Markham , ON , Canada ) ( Group IH ) IV ( Group IV ) milrinone . The investigator blind allocation study group . Anesthesia Patient Monitoring When patient arrive operating room , continuous monitor five-lead ECG ( lead II V5 ) , bispectral index ( BIS ) , pulse oximetry , invasive arterial pressure via radial artery start . Patients give midazolam 1.5-2 mg intravenously patient hold area . Anesthesia induce propofol 1-1.5 mg/kg , fentanyl 10-15 μg/kg , rocuronium 0.9 mg/kg . Target controlled infusion ( TCI ) TCI infusor ( Diprifusor™ TCI system ; Fresenius , Waltham , MA , USA ) use administer propofol anesthetic induction maintenance , infusion dose titrate achieve propofol effect-site concentration 2-2.5 μg/ml . Additional fentanyl 10-30 μg/kg/h rocuronium 20-30 mg/h administer maintain anesthesia , propofol concentration adjust maintain BIS score 40-60 . After tracheal intubation , volume-controlled ventilation oxygen air ( FiO2 0.6 , flow rate 100 ml/kg/min ) start tidal volume 10 ml/kg , respiration rate 12-14/min , inspiration : expiration ratio 1:2 , peak airway pressure low 25 cmH2O . Then , respiration rate adjust maintain end-tidal CO2 35-40 mmHg . An introducer pulmonary artery catheter ( Oximetrix™ Opticath catheter ; Abbot Laboratories , North Chicago , IL , USA ) place right internal jugular vein . A transesophageal echocardiography ( TEE ) probe place , intraoperative TEE use monitor ventricular valvular function throughout operation . The LV EF measure use modification Simpson 's method midesophageal 4 2 chamber view two-dimensional TEE image appropriate . During anesthesia induction obtain vascular access hemodynamic monitoring , synthetic hydroxyethylstarch ( Voluven™ ; Fresenius Kabi , Bad Homberg , Germany ) administer need maintain stable hemodynamics , bolus phenylephrine 50-100 μg administer intravenously treat refractory hypotension ( MAP &lt; 60 mmHg ) persist 1 min intravascular volume administration . After deliver study drug collect data , CPB moderate hypothermia ( rectal temperature 28-30ºC ) via crystalloid cardioplegia use surgical procedure . The MAP maintain 50-80 mmHg adjust pump flow administer 50 μg bolus phenylephrine CPB period . The IV milrinone infusion ( 0.5 μg/kg/min ) start release aortic cross-clamp continuous infusion norepinephrine start rectal temperature 35ºC need ; dosage titrate wean patient CPB maintain optimal hemodynamics post-CPB period group . Delivery Study Drug After perform sternotomy achieve stable hemodynamics , initiation CPB , study drug administer ; IH milirinone IV placebo ( 0.9 % normal saline 0.05 ml/kg ) IH placebo ( distilled water ) IV bolus milrinone ( 50 μg/kg ) administer Group IH IV , respectively . Milrinone use commercial concentration ( 1.0 mg/ml ) inhalation IV administration . The reservoir nebulizer ( MiniHeart™ ; Westmed , Tucson , AZ , USA ) inspiratory limb ventilator circuit ( 90 cm proximal Y-piece ) fill milrinone placebo . The milrinone placebo reservoir nebulized fix operate flow 2 L/min O2 ( per manufacturer 's recommendation ) deliver 10 min ventilator flow rate 100 ml/kg/min avoid rebreathing expiratory flow , may produce contamination interaction nebulized milrinone CO2 absorbent ( Fig . 1 ) . The aerosol size delivery rate nebulized drug assume 1.0-2.5 μm 45-65 μL per gas flow , respectively , accord manufacturer 's manual nebulizer . Excess inspiratory gas flow nebulizer compensate adjustment minute ventilation setting ventilator , keep minute ventilation constant . Inspiratory oxygen fraction ( FiO2 ) keep constant throughout procedure . If MAP decrease 60 mmHg , inhalation study drug stop patient exclude study . Hemodynamic Data The following data obtain 10 min completely administer study drug : mean arterial pressure ( MAP ) , mean pulmonary arterial pressure ( MPAP ) , central venous pressure ( CVP ) , pulmonary arterial occlusion pressure ( PAOP ) , transpulmonary pressure gradient ( TPG= mean PAP-PAOP ) , thermodilution cardiac output ( CO ) , systemic vascular resistance ( SVR ) , pulmonary vascular resistance ( PVR ) , arterial O2 tension ( PaO2 ) , mixed venous O2 saturation ( SvO2 ) , TEE measure EF . Statistical Analysis Intergroup comparison change SVR , PVR , PVR/SVR ratio , TPG use identify selective pulmonary vasodilation . The data administration compare use paired t-test . If data pass normality test , Wilcoxon signed-rank test use . Intergroup data compare use t-test . The need bolus phenylephrine due hypotension pre-CPB period CPB compare use Fisher 's exact test . Statistical significance assume p &lt; 0.05 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<mesh_term>Milrinone</mesh_term>
	<criteria>patient undergoing mitral valve surgery chronic mitral regurgitation estimate pulmonary hypertension ( systolic PAP &gt; 50 mmHg estimate velocity tricuspid valve regurgitation preoperative transthoracic echocardiography ) patient agree participate study sign write informed consent preoperative supraventricular tachycardia ( SVT ) , atrial fibrillation , atrial flutter , multiple ventricular ectopic contraction , continuous inotropic support , LV ejection fraction ( EF ) &lt; 30 % , emergent surgery , obstructive cardiomyopathy , bronchial asthma biochemical evidence hepatic disease renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>inhale milrinone</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>mitral regurgitation</keyword>
	<keyword>mitral valve surgery</keyword>
</DOC>